Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts.

Abstract

Ranolazine is a clinically approved drug for treating cardiac ventricular dysrhythmias and angina. Its mechanism(s) of protection is not clearly understood but evidence points to blocking the late Na+ current that arises during ischemia, blocking mitochondrial complex I activity, or modulating mitochondrial metabolism. Here we tested the effect of ranolazine treatment before ischemia at the mitochondrial level in intact isolated hearts and in mitochondria isolated from hearts at different times of reperfusion. Left ventricular (LV) pressure (LVP), coronary flow (CF), and O2 metabolism were measured in guinea pig isolated hearts perfused with Krebs-Ringer's solution; mitochondrial (m) superoxide (O2·-), Ca2+, NADH/FAD (redox state), and cytosolic (c) Ca2+ were assessed on-line in the LV free wall by fluorescence spectrophotometry. Ranolazine (5 μM), infused for 1 min just before 30 min of global ischemia, itself did not change O2·-, cCa2+, mCa2+ or redox state. During late ischemia and reperfusion (IR) O2·- emission and m[Ca2+] increased less in the ranolazine group vs. the control group. Ranolazine decreased c[Ca2+] only during ischemia while NADH and FAD were not different during IR in the ranolazine vs. control groups. Throughout reperfusion LVP and CF were higher, and ventricular fibrillation was less frequent. Infarct size was smaller in the ranolazine group than in the control group. Mitochondria isolated from ranolazine-treated hearts had mild resistance to permeability transition pore (mPTP) opening and less cytochrome c release than control hearts. Ranolazine may provide functional protection of the heart during IR injury by reducing cCa2+ and mCa2+ loading secondary to its effect to block the late Na+ current. Subsequently it indirectly reduces O2·- emission, preserves bioenergetics, delays mPTP opening, and restricts loss of cytochrome c, thereby reducing necrosis and apoptosis.

• Authors: Mohammed Aldakkak, Amadou K S Camara, James S Heisner, Meiying Yang, David F Stowe
• Journal: Pharmacological research (Pharmacol Res) Vol. 64 Issue 4 Pg. 381-92 (Oct 2011) ISSN: 1096-1186 [Electronic] Netherlands
• PMID: 21741479 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: Copyright © 2011 Elsevier Ltd. All rights reserved.

Chemical References

• Acetanilides
• Enzyme Inhibitors
• Piperazines
• Ranolazine
• Calcium

Topics

• Acetanilides (pharmacology, therapeutic use)
• Animals
• Calcium (metabolism)
• Enzyme Inhibitors (pharmacology, therapeutic use)
• Guinea Pigs
• Heart (drug effects)
• Membrane Potential, Mitochondrial (drug effects)
• Mitochondria, Heart (drug effects, metabolism)
• Myocardial Reperfusion Injury (metabolism, prevention & control)
• Oxidative Stress (drug effects)
• Piperazines (pharmacology, therapeutic use)
• Ranolazine